Evidence map›Paper›PMID 37087370›Full record

Trial reportThe Lancet. Digital health2023

Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial.

Benjamin H Kann, Jirapat Likitlersuang, Dennis Bontempi, Zezhong Ye, Sanjay Aneja, Richard Bakst, Hillary R Kelly, Amy F Juliano, Sam Payabvash, Jeffrey P Guenette and 11 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in The Lancet. Digital health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06829147 (Development and Validation of a Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma Using Histologic Whole Slide Images and Time-dependent Magnetic Resonance Images), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
23.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06829147 recruitingnot on this mapstarted 2024, after this paper: background citation

Development and Validation of a Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma Using Histologic Whole Slide Images and Time-dependent Magnetic Resonance Images

TypeobservationalSponsorSun Yat-sen UniversityRan2024 to 2026Enrolled500ConditionsNasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 1 country.

Benjamin H KannDepartment of Radiation Oncology, Harvard Medical School, Boston, MA, USA; Mass General Brigham Artificial Intelligence in Medicine Program, Boston, MA, USA. Electronic address: benjamin_kann@dfci.harvard.edu.
Jirapat LikitlersuangDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Mass General Brigham Artificial Intelligence in Medicine Program, Boston, MA, USA.
Dennis BontempiDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Mass General Brigham Artificial Intelligence in Medicine Program, Boston, MA, USA.
Zezhong YeDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Mass General Brigham Artificial Intelligence in Medicine Program, Boston, MA, USA.
Sanjay AnejaDepartment of Therapeutic Radiology, New Haven, CT, USA.
Richard BakstIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Hillary R KellyMass Eye and Ear, Mass General Hospital, Boston, MA, USA.
Amy F JulianoMass Eye and Ear, Mass General Hospital, Boston, MA, USA.
Sam PayabvashDepartment of Radiology, New Haven, CT, USA.
Jeffrey P GuenetteDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ravindra UppaluriDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Danielle N MargalitDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan D SchoenfeldDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Roy B TishlerDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Robert HaddadDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hugo J W L AertsDana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Mass General Brigham Artificial Intelligence in Medicine Program, Boston, MA, USA; Department of Radiology, Maastricht University, Maastricht, Netherlands.
Joaquin J GarciaDepartment of Pathology, Mayo Clinic, Rochester, MN, USA.
Yael FlamandDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
Rathan M SubramaniamDepartment of Radiology and Nuclear Medicine, University of Notre Dame Australia, Sydney, NSW, Australia; Department of Radiology, Duke University, Durham, NC, USA.
Barbara A BurtnessYale School of Medicine, New Haven, CT, USA.
Robert L FerrisDepartment of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Dana-Farber Cancer Institute · USHarvard University · USMassachusetts Eye and Ear Infirmary · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USUPMC Hillman Cancer Center · USYale University · US

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5M
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer CenterUG1CA233184 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ADAM M BRUFSKY, John Munn Kirkwood · 2019 to 2026
$7.7M
Yale Cancer Center NCTN LAPSUG1CA233337 · NCI · YALE UNIVERSITY · PI ANNE C CHIANG · 2019 to 2026
$6.0M
The Duke University - Duke Cancer Institute National Clinical Trials Network LAPS (UG1) Support GrantUG1CA233253 · NCI · DUKE UNIVERSITY · PI John H Strickler, Alexandra Thomas · 2019 to 2026
$3.7M
Quantitative Radiomics System Decoding the Tumor PhenotypeU24CA194354 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.5M
Genotype and Imaging Phenotype Biomarkers in Lung CancerU01CA190234 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.3M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P50 CA097190NCI NIH HHS U01 CA190234NCI NIH HHS U01 CA209414NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA194354NCI NIH HHS UG1 CA232760NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233184NCI NIH HHS UG1 CA233253NCI NIH HHS UG1 CA233337NIDCR NIH HHS K08 DE030216
6 · The paper itself

Abstract

backgroundPretreatment identification of pathological extranodal extension (ENE) would guide therapy de-escalation strategies for in human papillomavirus (HPV)-associated oropharyngeal carcinoma but is diagnostically challenging. ECOG-ACRIN Cancer Research Group E3311 was a multicentre trial wherein patients with HPV-associated oropharyngeal carcinoma were treated surgically and assigned to a pathological risk-based adjuvant strategy of observation, radiation, or concurrent chemoradiation. Despite protocol exclusion of patients with overt radiographic ENE, more than 30% had pathological ENE and required postoperative chemoradiation. We aimed to evaluate a CT-based deep learning algorithm for prediction of ENE in E3311, a diagnostically challenging cohort wherein algorithm use would be impactful in guiding decision-making.

methodsFor this retrospective evaluation of deep learning algorithm performance, we obtained pretreatment CTs and corresponding surgical pathology reports from the multicentre, randomised de-escalation trial E3311. All enrolled patients on E3311 required pretreatment and diagnostic head and neck imaging; patients with radiographically overt ENE were excluded per study protocol. The lymph node with largest short-axis diameter and up to two additional nodes were segmented on each scan and annotated for ENE per pathology reports. Deep learning algorithm performance for ENE prediction was compared with four board-certified head and neck radiologists. The primary endpoint was the area under the curve (AUC) of the receiver operating characteristic.

findingsFrom 178 collected scans, 313 nodes were annotated: 71 (23%) with ENE in general, 39 (13%) with ENE larger than 1 mm ENE. The deep learning algorithm AUC for ENE classification was 0·86 (95% CI 0·82-0·90), outperforming all readers (p<0·0001 for each). Among radiologists, there was high variability in specificity (43-86%) and sensitivity (45-96%) with poor inter-reader agreement (κ 0·32). Matching the algorithm specificity to that of the reader with highest AUC (R2, false positive rate 22%) yielded improved sensitivity to 75% (+ 13%). Setting the algorithm false positive rate to 30% yielded 90% sensitivity. The algorithm showed improved performance compared with radiologists for ENE larger than 1 mm (p<0·0001) and in nodes with short-axis diameter 1 cm or larger.

interpretationThe deep learning algorithm outperformed experts in predicting pathological ENE on a challenging cohort of patients with HPV-associated oropharyngeal carcinoma from a randomised clinical trial. Deep learning algorithms should be evaluated prospectively as a treatment selection tool.

fundingECOG-ACRIN Cancer Research Group and the National Cancer Institute of the US National Institutes of Health.

Indexed as

CarcinomaDeep LearningOropharyngeal NeoplasmsPapillomavirus InfectionsAlgorithmsExtranodal ExtensionHuman Papillomavirus VirusesHumansRetrospective StudiesTomography, X-Ray Computed

Identifiers

PMID37087370
PMCPMC10245380
OpenAlexW4366692757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.